Tom Pike. Chairman. Mr. Pike is actively involved with a number of life science companies and organizations in the capacity of consultant and/or board member. His past experience range from and Chairman & CEO of Clavis Pharma ASA, a public oncology drug development company to Partner of the venture capital group NeoMed Management and more than 18 years’ experience as CEO, sales and marketing director, business alliance manager and other positions at Hoffmann-La Roche in Switzerland and Norway. He has served on the board (past Chairman) of the Norwegian Association of Pharmaceutical Manufacturers for six years. Mr. Pike is a Norwegian and British citizen and holds a B.Sc. Honours in Pharmacology.



Yihai Cao, PhD, Prof, born in Shandong, China, received his medical training at the Medical School, Shandong University in 1983. 1983-1986, he received further basic and clinical training from the Chinese Academy of Medical Sciences and from the Ludwig Institute for Cancer Research, Switzerland. He obtained his Ph.D. degree in 1993 from the Karolinska Institutet, followed by a 3-yr postdoctoral training period at the Harvard Medical School, Children's Hospital (Dr. Judah Folkman´s Laboratory), Boston, Massachusetts, USA. He returned to the Karolinska Institutet in 1996 and became a full professor in 2004. He received a honorary medical degree (M.D.) from Copenhagen University, Denmark, 2006. He is currently a guest professor at the Linköping University, Sweden. He received the Fernstrom research prize. In 2010, Dr Cao received the distinguished professor award at the Karolinska Institutet. Dr. Cao also received the ERC-advanced research grant award for being the top scientist in Europe. His research interests include molecular mechanisms of pathological angiogenesis that contributes to obesity, metabolic diseases, diabetic complications, cancer, metastasis, and cardiovascular diseases, with emphasis on clinical relevance and translational research. He has published more than 160 research articles.

Mario Fsadni, MBChB, MSc, MRCOphth, LLM is Managing Director of International Pharm-Med Ltd., specialised in Ophthalmic product development and medical affairs. After several years working as a hospital based ophthalmologist, Dr Fsadni joined the pharmaceutical industry over 20 years ago. He brings a broad, hands on experience and a proven track record in successful global product development and commercialisation. Previous posts include global Medical Director at Novartis Ophthalmics AG, and Director of Product Development Ophthalmology (EMEA) at Allergan Ltd.

Jonathan Hepple, Ph D, Venture investor in life science companies since 1998. Founder of Rosetta Capital, a leading international secondary venture firm, focused on life sciences. Rosetta's investments include Enobia Pharmaceuticals, GeminX Pharmaceuticals, Cytochroma, Forward Pharma and Zealand Pharmaceuticals. Also Partner at Seroba Kernel Life Sciences, a European venture firm, investing in biotech and medtech. Current board seats include Axelar AB, Clanotech AB, Covagen AG and Opsona Therapeutics.

   
ClanoTech AB • Fogdevreten 2 • S-17165 Solna • Sweden • Org. nr. 556706-6658 • Registered office: Solna
 

-